Navigation Links
New Vaccine To Be Used For First Time In Polio Outbreak Response

reach every child under five years old.

Dedicated donor support and strong partnerships with the private sector have enabled the previous campaign in Yemen as well as swift development of the mOPV1 vaccine. However, a global funding gap of US$ 50 million must urgently be filled by July, to finance continued intensification of immunization campaigns in the second half of the year.

Global eradication efforts have reduced the number of polio cases from 350 000 annually in 1988 to 1267 cases in 2004. Six countries remain polio-endemic, with a further six where polio transmission is re-established. Concern is high that the ongoing outbreak of polio in Africa might lead to re-infection of more countries in the polio-free Horn of Africa and the Middle East. Yemen is the most recent of fifteen polio-free countries that have reported cases of polio since the epidemic began in late 2003.


'"/>

Source:WHO


Page: 1 2

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. EuroVacc 02 HIV Vaccine Trial Begins
9. Active Vaccine Prevents Mice From Developing Prion Disease
10. Boosting The BCG Vaccine To Beat Tuberculosis
11. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
Post Your Comments:
Breaking Biology News(10 mins):Improving the odds 2Biogen Idec's oral compound BG-12 achieves development milestones in MS and RA 2Study shows nearly 1/3 of human genome is involved in gingivitis 2Study shows nearly 1/3 of human genome is involved in gingivitis 3Winners of the Addressing Psoriasis 28TM 29 Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn 50794 1Winners of the Addressing Psoriasis 28TM 29 Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn 50794 2Winners of the Addressing Psoriasis 28TM 29 Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn 50794 3Winners of the Addressing Psoriasis 28TM 29 Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn 50794 4Winners of the Addressing Psoriasis 28TM 29 Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn 50794 5Winners of the Addressing Psoriasis 28TM 29 Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn 50794 6Ready for relapse 3A Molecule helps breast cancer cells to survive in the bone marrow 50791 1Ready for relapse 3A Molecule helps breast cancer cells to survive in the bone marrow 50791 2Orange County Cosmetic Plastic Surgeon Reaches Out to Community with New Website 50787 1Orange County Cosmetic Plastic Surgeon Reaches Out to Community with New Website 50787 2Orange County Cosmetic Plastic Surgeon Reaches Out to Community with New Website 50787 3
Breaking Biology Technology:Vivakor Announces Additions to Board of Directors and Scientific Advisory Board 2Vivakor Announces Additions to Board of Directors and Scientific Advisory Board 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Cell Biosciences Acquires Protein Forest 2Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2